Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Inclusion Criteria: * Confirmed newly diagnosed symptomatic acute venous thromboembolism (VTE) \[proximal lower extremity deep vein thrombosis (DVT) or segmental or greater pulmonary embolism (PE)\] * Age ≥ 18 years old * Informed consent obtained Exclusion Criteria: * Have received \> 72 hours of therapeutic anticoagulation * Creatinine clearance \< 30 ml/min calculated with the Cockcroft-Gault formula * Any contraindication for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to: * active bleeding, * active malignancy, defined as a) diagnosed with cancer within the past 6 months; or b) recurrent, regionally advanced or metastatic disease; or c) currently receiving treatment or have received any treatment for cancer during the 6 months prior to randomization; or d) a hematologic malignancy not in complete remission, * weight \> 120 kg, * liver disease (Child-Pugh Class B or C), * use of contraindicated medications * another indication for long-term anticoagulation (e.g. atrial fibrillation) * pregnant (note below) or breastfeeding (Note: as reported by the patient or a pregnancy test will be ordered at the discretion of the treating physician for women of childbearing potential as per standard of care)